Lycera Corporation

Merck Sharp + Dohme Corp.

University of Michigan

Chad A VanHuis

Thomas Daniel Aicher

Clarke Bentley Taylor

Kun Liu

Kenneth Jay Barr

Brian M Andresen

Nunzio Sciammetta

Matthew H Daniels

Vladimir Simov

John K MacLean

Corey E Bienstock

Yuan Liu

Neville J Anthony

William L Thomas

Gary D Glick

Arthur Glenn Romero

Alexander Ross Hurd

Donald James Skalitzky

Peter Laurence Toogood

Zhan Wang

Catherine M White

Blair T Lapointe

Fernando Padilla

Karin Ann Stein

Matthew N Mattson

Wesley B Trotter

Erik Krogh-Jespersen

Carl Kaub

Alexander R Hurd

William David Thomas

The invention provides aryl dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds, pharmaceutical compositions, methods of promoting ROR&#x3b3; activity, methods of increasing the amount of IL-17 in a subject, and methods of treating cancer and other medical disorders using such compounds.

Aryl dihydro-2H benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of ROR&#x3b3; and the treatment of disease

The invention provides certain bicylic heterocyclic compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein X, X, R, R, R, R4, and Cy are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds of the Formula (I) or pharmaceutically acceptable salts thereof, and methods of using the compounds of the Formula (I) or pharmaceutically acceptable salts thereof or pharmaceutical compositions comprising the same for treating diseases or conditions mediated by RORgammaT. 

Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease

The invention provides aryl dihydro-2H-benzo[b] [1,4]oxazine sulfonamide and related compounds, pharmaceutical compositions, methods of promoting RORy activity, methods of increasing the amount of IL-17 in a subject, and methods of treating cancer and other medical disorders using such compounds.

Aryl dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of ROR&#x3b3; and the treatment of disease

The invention provides indazolyl thiadiazolamines and related compounds, pharmaceutical compositions, methods of inhibiting Rho-associated protein kinase, and methods of treating inflammatory disorders, immune disorders, fibrotic disorders, and other medical disorders using such compounds. An exemplary indazolyl thiadiazolamine compound is an N-(3-(5-((1H-indazol-5-yl)amino)-1,2,4-thiadiazol-3-yl)phenyl)-heteroaryl-carboxamide compound.

Indazolyl-1,2,4-thiadiazolamines and related compounds for inhibition of Rho-associated protein kinase and the treatment of disease

The invention provides tetrahydroquinoline sulfonamide compounds, tetrahydronaphthalene sulfonyl compounds, and related compounds, pharmaceutical compositions, methods of promoting RORy activity, methods of increasing the amount of IL-17 in a subject, and methods of treating cancer and other medical disorders using such compounds.

Tetrahydroquinoline sulfonamide and related compounds for use as agonists of ROR&#x3b3; and the treatment of disease

The invention provides dihydro-2H-benzo[b] [1,4]oxazine sulfonamide and related compounds, pharmaceutical compositions, methods of promoting ROR&#x3b3; activity, methods of increasing the amount of IL-17 in a subject, and methods of treating cancer and other medical disorders using such compounds.

Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of ROR&#x3b3; and the treatment of disease

The invention provides certain bicyclic heterocyclic compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein X, X, R, R, R, R, and Cy are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds of the Formula (I) or pharmaceutically acceptable salts thereof, and methods of using the compounds of the Formula (I) or pharmaceutically acceptable salts thereof or pharmaceutical compositions comprising the same for treating diseases or conditions mediated by RORgammaT. 

The invention provides pyrazolyl guanidine compounds that inhibit FF-ATPase, and methods of using pyrazolyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.

[object Object]

The invention provides tetrahydroquinoline sulfonamide compounds, tetrahydronaphthalene sulfonyl compounds, and related compounds, pharmaceutical compositions, methods of promoting ROR&#x3b3; activity, methods of increasing the amount of IL-17 in a subject, and methods of treating cancer and other medical disorders using such compounds.

The invention provides certain benzoxazine compounds of the Formula (I) or pharmaceutically acceptable salts thereof wherein R, R, R, R, R, R, R, R, and Cy are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds of the Formula (I) or pharmaceutically acceptable salts thereof, and methods of using the compounds of the Formula (I) or pharmaceutically acceptable salts thereof or pharmaceutical compositions comprising the same for treating diseases or conditions mediated by RORgammaT. 

Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease

The invention provides certain benzoxazine compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, R, R, and Cy are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds of the Formula (I) or pharmaceutically acceptable salts thereof, and methods of using the compounds of the Formula (I) or pharmaceutically acceptable salts thereof or pharmaceutical compositions comprising the same for treating diseases or conditions mediated by RORgammaT. 

Growing community of inventors

Hartland, MI, United States of America

Chad A VanHuis